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The stable incidence of new leprosy cases suggests that transmission of infection continues despite worldwide implementation of
MDT. Thus, speciﬁc tools are needed to diagnose early stage Mycobacterium leprae infection, the likely sources of transmission.
M. leprae antigens that induce T-cell responses in M. leprae exposed and/or infected individuals thus are major targets for new
diagnostic tools. Previously, we showed that ML1601c was immunogenic in patients and healthy household contacts (HHC).
However, some endemic controls (EC) also recognized this protein. To improve the diagnostic potential, IFN-γ responses to
ML1601c peptides were assessed using PBMC from Brazilian leprosy patients and EC. Five ML1601c peptides only induced IFN-γ
in patients and HHC. Moreover, 24-hour whole-blood assay (WBA), two ML1601c peptides could assess the level of M. leprae
exposure in Ethiopian EC. Beside IFN-γ,a l s oI P - 1 0 ,I L - 6 ,I L - 1 β,T N F - α, and MCP-1 were increased in EC from areas with high
leprosy prevalence in response to these ML1601c peptides. Thus, ML1601c peptides may be useful for diﬀerentiating M. leprae
exposed or infected individuals and can also be used to indicate the magnitude of M. leprae transmission even in the context of
various HLA alleles as present in these diﬀerent genetic backgrounds.
1.Introduction
Leprosy is a treatable infection caused by Mycobacterium
leprae (M. leprae) involving skin and peripheral nerves and
is inﬂuenced by genetic and environmental factors [1–3].
The infection can result in skin lesions, nerve degeneration,
and deformities. Despite a spectacular decrease in global
prevalence since 1982, transmission of leprosy is sustained as
evidenced by the hundreds of thousand new cases of leprosy
that keep being detected globally every year: 244,796 new
cases of leprosy were detected during 2009 amongst whom
22,485 were children and the registered prevalence at the
beginning of 2010 was 211,903 cases [4].
In Brazil, for example, the number of new cases detected
during 2009 was 37,610 resulting in a registered prevalence
of 38,179 at the end of ﬁrst quarter of 2010 [4]. These
ﬁgures demonstrate that M. leprae-infected contacts and
persons with subclinical, undiagnosed leprosy, likely the
major sources of unidentiﬁed transmission, are an inces-
sant source of active transmission. Despite many eﬀorts,
prediction of disease development in aﬀected individuals
is still not possible nor can we detect asymptomatic M.
leprae infection. Diagnosis of leprosy is usually based on
clinical features and skin smear results including the number
of skin lesions. M. leprae is not cultivable, and bacterial
enumeration by microscopic examination is required for2 Journal of Tropical Medicine
leprosy classiﬁcation, choice in choosing and monitoring
chemotherapy regimens, and diagnosis of relapse. However,
detection and quantiﬁcation using standard microscopy
yields data of limited speciﬁcity and sensitivity. Thus, in
order to complement current clinical methods, especially
for PB patients, and to allow informed decision making on
who needs treatment at a preclinical stage, several groups are
investigatingdesignofimproveddiagnostictools.Thesetools
will reduce transmission, prevent functional disabilities and
stigmatizing deformities, and facilitate leprosy eradication,
especially in individuals at risk for developing leprosy such
as close contacts of leprosy patients.
Assays have been developed that detect M. leprae-speciﬁc
IgM antibodies against PGL-I [5, 6], which are able to
identify multibacillary (MB) leprosy patients (with strong
humoralimmunitytoM.leprae),butthesefailtodetectmost
paucibacillary (PB) leprosy patients and leprosy patients’
contacts as these typically develop strong cellular but not
humoral immunity. One of the hurdles hampering T-cell-
based diagnostic tests is that M. leprae antigens can cross-
react at the T-cell level with antigens present in other
mycobacteria, like M. tuberculosis or BCG even if the homo-
logy is relatively low as is the case for ESAT-6 and CFP-10
[7, 8]. Using comparative genomics, we previously identiﬁed
candidate proteins highly restricted to M. leprae which
showed promising features with respect to application in
leprosy diagnostics [9, 10].
For speciﬁc detection of M. tuberculosis infection, com-
mercially available IFN-γ release assays (IGRAs) like Quanti-
FERON-TB Gold have been developed [11]: these tests are
based on cellular immune responses induced by a cocktail of
peptides derived from ESAT-6 (Rv3875), CFP-10 (Rv3874),
and TB7.7 (Rv2654) that are selectively expressed by M.
tuberculosis and deleted from all (nonvirulent) BCG strains
and most other NTMs [11]. This has inspired research into
the feasibility of developing similar peptide-based assays
for the identiﬁcation of asymptomatic leprosy: encouraging
results have been generated indicating that some synthetic
peptides induce speciﬁc responses in individuals exposed to
M. leprae and could potentially be developed into a rapid
test for the detection of M. leprae infection [10, 12, 13].
In contrast to TB, however, ESAT-6- or CFP-10-derived
peptides will not be useful due to the cross-reactive T-cell
responses they induce in TB patients [7, 8].
SinceT-cellreactivitytopeptidesareHLA-restricted[14–
16], the use of a pool composed of several diﬀerent M.
leprae peptides, in analogy to the pool of peptides applied
in the QuantiFERON-TB Gold tests, will increase sensitivity
[17, 18], while avoiding T-cell cross-reactivity.
In order to improve sensitivity of a speciﬁc diagnostic
peptide mixture, we have in this study extended the num-
ber of peptides with potential to distinguish exposure to M.
leprae from BCG vaccination and exposure to other myco-
bacteria in a future diagnostic tool.
The protein ML1601c was previously identiﬁed by us as
highly immunogenic in M. leprae-exposed Brazilian individ-
uals [9], and although it does not contain a homologous
sequence in M. tuberculosis, it does have an orthologue in M.
avium paratuberculosis, MAP3249, which is 33% identical to
Table 1: ML1601c synthetic peptides.
Peptide no. Amino acid sequence∗ Amino acid
identity∗∗
11 AHHNAHAAPAFLWSGLVSA 42% (8/19)
12 FLWSGLVSAAVLIADGRGE 52% (10/19)
13 AVLIADGRGEDTYLPIISIY 40% (8/20)
14 DTYLPIISIYLARGNELKPN 10% (2/20)
15 LARGNELKPNPLLSVIYVEH 25% (5/20)
16 PLLSVIYVEHLLVLFYQSVG 35% (7/20)
17 LLVLFYQSVGDHCGFGRYDF 45% (9/20)
18 DHCGFGRYDFGKTMVLACYG 50% (10/20)
19 GKTMVLACYGCVGTRSLLSG 30% (6/20)
20 CVGTRSLLSGRDDDLVTSVP 15% (3/20)
3 RDDDLVTSVPPCGRASVVHRS 0% (0/21)
∗Synthetic peptides overlapping ML1601c are shown in single-letter amino
acid code.
∗∗Amino acid sequences of ML1601c (M. leprae TN and BR4923) peptides
were analyzed using BLAST (http://blast.ncbi.nlm.nih.gov/); amino acids
that are identical to the MAP3249 are depicted in bold.
ML1601c.Toidentifysinglepeptidesthatareonlyrecognized
by M. leprae-exposed and/or infected individuals, we here
analyzed IFN-γ production in Brazilian leprosy patients
and controls in response to overlapping ML1601c peptides
covering the whole protein.
2.MaterialsandMethods
2.1. Synthetic Peptides. ML1601c overlapping peptides (Ta-
ble 1: two 19-mers with 9 amino acid overlap; eight 20-mers
with 10 amino acid overlap; one 21-mer with 10 amino acids
overlap) were purchased from Peptide 2.0 Inc. (Chantilly,
VA, USA). Homogeneity and purity were conﬁrmed by
analytical HPLC and by mass spectrometry. Purity of all
peptideswas ≥80%.Allimpuritiesconsistofshorterversions
of the peptides caused by <100% coupling eﬃciency in
each round of synthesis. Aliquots of identical batches of the
synthetic peptides were tested in Brazil, Ethiopia, and The
Netherlands.
2.2. Recombinant ML1601c Protein. The ML1601c gene was
ampliﬁed by PCR from genomic DNA of M. leprae and
cloned using the Gateway technology platform (Invitro-
gen, Carlsbad, CA, USA) with pDEST17 expression vector
containing an N-terminal histidine tag (Invitrogen) [19].
Sequencing was performed on selected clones to conﬁrm
identity of all cloned DNA fragments. Recombinant proteins
were overexpressed in E. coli BL21 (DE3) and puriﬁed as
described to remove any traces of endotoxin. Each puri-
ﬁed recombinant protein was analyzed by 12% SDS-PAGE
followed by Coomassie Brilliant Blue staining and western
blotting with an anti-His antibody (Invitrogen) to conﬁrm
size and purity. Endotoxin contents were below 50IU per mg
recombinant protein as tested using a Limulus Amebocyte
Lysate (LAL) assay (Cambrex, East Rutherford, NJ, USA).
Recombinant ML1601c protein was tested to exclude proteinJournal of Tropical Medicine 3
nonspeciﬁc T-cell stimulation and cellular toxicity in IFN-γ
release assays using PBMC of in vitro PPD-negative, healthy
Dutch donors recruited at the Sanquin Blood Bank, Leiden,
TheNetherlands.Noneofthesecontrolshadexperiencedany
known prior contact with leprosy or TB patients.
2.3. M. leprae Whole-Cell Sonicate. Irradiated armadillo-
derived M. leprae whole cells were probe-sonicated with a
Sanyo sonicator to >95% breakage. This material was pro-
vided through the NIH/NIAID “Leprosy Research Support”
Contract N01 AI-25469 from the Colorado State University
(these reagents are now available through the Biodefense and
Emerging Infections Research Resources Repository listed
at http://www.beiresources.org/TBVTRMResearchMaterials/
tabid/1431/Default.aspx).
2.4.StudySubjects. TwentytwoBrazilianleprosypatients(11
paucibacillary (PB) leprosy patients and 11 multibacillary
(MB)) were recruited from the Leprosy Out-Patient Unit,
Leprosy Laboratory (Oswaldo Cruz Institute, Rio de Janeiro
RJ, Brazil) and from the Duque de Caxias Outpatient Units
(Health Department, Duque de Caxias, RJ, Brazil). Leprosy
patients were diagnosed and classiﬁed based on clinical,
bacteriological, and if possible histopathological ﬁndings.
MB patients were treated with rifampicin, dapsone, and
clofazimine. PB patients were treated with rifampicin and
dapsone. All MB patients were skin-slit smear positive
whereas PB patients were all skin-slit smear negative. All
patients were tested before MDT was initiated. As controls,
19 healthy household contacts of MB leprosy patients
(HHC),8tuberculosispatients(TB),and17healthyendemic
controls (EC) were recruited from Duque de Caxias (n = 7)
and the city of Rio de Janeiro (n = 10). Leprosy detection
rates at the time of recruitment were 1.26 per 10,000 in
Rio de Janeiro and 3.40 per 10,000 in Duque de Caxias
(Ministry of Health of Brazil; http://www.datasus.gov.br/).
FromEthiopia34healthycontrolsweretested:18EChigh were
derived from a subcity of Addis Ababa (Kolfe Keranio Clinic)
with a prevalence rate of 1.5 per 10,000 (72 in 465,811),
whereas 16 EClow were derived from areas with a prevalence
rate of 0.36 per 10,000 (10 in 273,310). Prevalence rates in
Ethiopia were calculated based on the number of patients in
the health centers provided by the personnel of each health
center. TB patients were recruited from the Ambulatory
Service, District Hospital of Raphael de Paula e Souza, Rio
de Janeiro RJ, Brazil. As nonendemic controls 21 Dutch
healthy individuals (NEC) were recruited at the Sanquin
Blood Bank, Leiden, The Netherlands. None of the NEC had
experienced any known prior contact with leprosy patients.
Informed consent was obtained from all individuals before
venepuncture. Ethical approval of the study protocol was
obtained through the appropriate local ethics committees.
2.5. Lymphocyte Stimulation Tests (LSTs). Venous blood was
obtained from study participants in heparinized tubes and
PBMC isolated by Ficoll density centrifugation. PBMCs
(1.5 × 106 cells/mL) were plated in triplicate cultures in 96-
well round-bottom plates (Costar Corporation, Cambridge,
M A ,U S A )i n2 0 0 μL/well of adoptive immunotherapy
medium (AIM-V, Invitrogen, Carlsbad, CA, USA). Synthetic
peptides, recombinant protein, M. leprae w h o l ec e l ls o n i c a t e
orPPD(puriﬁedproteinderivativeofM.tuberculosis,M ycos,
Loveland, CO, USA) were added at ﬁnal concentrations of
10μg/mL. As positive control stimuli SEB (staphylococcal
enterotoxin B: 1μg/mL; Toxin Technology, Inc., Sarasota,
FL, USA) or PHA (phytohemagglutinin; 2μg/mL; Sigma, St.
Louis, MO, USA) was used. After 6 days of culture at 37◦C
at 5% CO2 and 90% relative humidity, 110μL supernatants
were removed from each well; triplicates were pooled and
frozen in aliquots at −20◦C until further analysis.
2.6. Whole Blood Assays (WBAs). Venous undiluted hep-
arinized blood (450μL per well) was incubated in 48-
well plates at 37◦Ca t5 %C O 2 and 70% relative humidity
with 50μL of ML1601c peptide (p11 and p16) solution
(10μg/mLﬁnalconcentration).Bloodwasaddedtoeachwell
within 2 hours of collection. After 24h of culture, 180μL
of supernatants were removed from each well and frozen in
aliquots at −20◦C until further analysis.
2.7. IFN-γ ELISA. Detection of IFN-γ in culture super-
natants of in vitro cultured cells was performed by ELISA
(BD Bioscience) according to the manufacturer’s instruc-
tions. OD values were converted into concentrations using
Microplate Manager software, version 5.2.1 (Bio-Rad Labo-
ratories, Veenendaal, The Netherlands). The cut-oﬀ value to
deﬁne positive responses was set beforehand at 100pg/mL.
The assay sensitivity level was 20pg/mL. Values for unstimu-
lated whole blood cultures were typically <30pg/mL.
2.8. Multiplex Determination of Cytokines and Chemokines.
Accordingtothemanufacturer’sguidelines,18inﬂammatory
and immunomodulatory cytokines or chemokines (IL-1β,
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13,
IL-17, G-CSF, GM-CSF, IFN-γ, IP-10 (CXCL10), MCP-
1 (CCL2), MIP-1β (CCL4), and TNF) were measured
in unstimulated, antigen-stimulated, or mitogen-stimulated
samples by Bio-Plex Suspension Array System powered by
Luminex xMAP multiplex technology (Bio-Rad Laborato-
ries, Veenendaal, The Netherlands) and analyzed with the
Bio-Plex Manager Software 4.0 (Bio-Rad Laboratories, Vee-
nendaal, The Netherlands). After prewetting the ﬁlter with
assay solution, the beads were washed twice with washing
solution using 96-well multiscreen ﬁlter plates (Millipore),
an Aurum vacuum manifold and a vacuum pump (Bio-Rad
Laboratories, Veenendaal, The Netherlands). Supernatant
samples (50μL) were added to the plates, and the plates
were incubated 45 minutes at room temperature in the
dark at 300rpm on a plate shaker. After three washes,
12.5μL detection antibody cocktail was added per well, and
plates were incubated at room temperature in the dark for
30 minutes on a plate shaker. After three washes, 25μL
streptavidin-PE solution was added per well and incubated
for 10 minutes. After three washes, 100μLo fa s s a yb u ﬀer was
added to each well and the plates were placed in the Bio-Plex
System. From each well, a minimum of 100 analyte-speciﬁc4 Journal of Tropical Medicine
beads were analyzed for ﬂuorescence. A curve ﬁt was applied
to each standard curve according to the manufacturer’s
manual.Sampleconcentrationswereinterpolatedfromthese
standardcurves.Analyteconcentrationsoutsidetheupperor
lower limits of quantiﬁcation were assigned the values of the
limits of quantiﬁcation of the cytokine or chemokine.
2.9. Statistical Analysis. Diﬀerences in cytokine levels bet-
ween groups were analyzed with the two-tailed Mann-Whit-
ney U test for nonparametric distribution using Graph Pad
Prism (version 5). P values were corrected for multiple com-
parisons. The statistical signiﬁcance level used was P<0.05.
2.10. Factor Analysis. The factor analysis technique was ap-
plied to evaluate the IFN-γ production levels induced by
ML1601c and the ML1601c-derived peptides in order to
identify the diﬀerent patterns of response associated with
these stimuli and to group together peptides inducing
similar patterns of IFN-γ production. Three independent
factors representing combinations of the original variables
were determined. The factor loadings are the correlation
coeﬃcientsbetweentheoriginalvariablesorIFN-γ responses
to a given peptide and the factors (StatSoft, Inc. 2010, STA-
TISTICA, data analysis software system, version 9; http://
www.statsoft.com/).
3. Results
3.1. Identiﬁcation of M. leprae-Speciﬁc T-Cell Epitopes of
ML1601c in Brazilian Population Highly Endemic for Leprosy.
In view of its high immunogenicity in M. leprae-exposed
individuals[9],therecombinantproteinML1601cwastested
for induction of IFN-γ in PBMC derived from multibacillary
(MB)andpaucibacillary(PB)leprosypatients,healthyhouse
contacts (HHCs), tuberculosis (TB) patients, and healthy
controls (EC) from Brazil and from 21 Dutch (nonendemic)
control (NEC) individuals (Figure 1). As controls, stimu-
lation by M. leprae whole cell sonicate, puriﬁed protein
derivative (PPD) of M. tuberculosis and staphylococcal enter-
otoxin B (SEB) was also analyzed. As can be seen from Fig-
ure 1 all groups responded well to the SEB control with me-
dian production >2400pg/mL. For the Dutch NEC the
positive control PHA was used instead of SEB, inducing
overall higher IFN-γ responses in this group (Figure 1(a)).
PPD was highly immunogenic in all groups as well, be it
that IFN-γ responses to M. leprae showed more variability
as only three individuals responded well in the NEC group,
twointermediately,and16werenonrespondersforM.leprae.
Additionally, the MB patients did not or only barely respond
to M. leprae, which is a general phenomenon for this type
of leprosy patients. Similar to PPD, ML1601c protein did
not induce signiﬁcantly diﬀerent IFN-γ production in EC
comparedto NEC nor compared tothe HHC group, whereas
MB patients again responded less well than the ﬁve other test
groups.Insummary,thesedataindicatethatIFN-γ responses
induced by ML1601c protein cannot be used to discriminate
between M. leprae-exposed and nonexposed individuals.
Table 2: Use of factor analysis for grouping together peptides and
protein inducing similar patterns of IFN-γ responses∗.
Factor 1 Factor 2 Factor 3
p11 0.9630 0.0767 0.1875
p12 0.9401 0.0452 0.1643
p13 0.9219 0.0913 0.2498
p14 0.7010 0.0961 0.3563
p15 0.1877 −0.0058 0.9473
p16 0.9243 0.0214 0.1205
p17 0.1487 0.9606 0.0324
p18 0.5554 −0.0218 0.3223
p19 0.7157 −0.0095 0.3751
p20 0.3068 0.0327 0.8787
p3 0.9524 0.0701 0.1830
ML1601c −0.0081 0.9788 −0.0103
∗Values indicative of high correlation of a peptide IFN-γ response with one
factor are depicted in bold. Factor analysis of the IFN-γ responses induced
by the ML1601c protein and ML1601c peptides was performed with IFN-γ
values observed in MB, PB, HHC, TB, and EC (STATISTICA, data analysis
software system, version 9). The3 factors arenew andindependentvariables
that capture the characteristics of the original variables (IFN-γ responses
to the peptides and ML1601c protein in the diﬀerent groups). The factor
loadings indicative of the correlation of the IFN-γ responses induced by
a peptide with each factor are shown. The 0.80000 value was arbitrarily
selected for indicating a high correlation of one peptide with a given factor.
In view of this nondiscriminatory nature of the IFN-
γ responses induced by the ML1601c protein in Brazilian
individuals and due to the fact that ML1601c contains
sequences similar or identical to M. avium paratuberculosis
(MAP3249), peptides overlapping the entire sequence of
ML1601c (Table 1) were synthesized. Analysis of IFN-γ
responses induced by these ML1601c synthetic peptides in
PBMC is shown in Figure 2: again, similar to stimulation
with ML1601c protein, MB patients responded less well than
PB patients and HHCs. In these latter two groups each
ML1601c peptide was recognized by ≥1 (HHC) or ≥3 (PB)
individuals with a maximum of 11 HHC recognizing p17. In
contrast to the responses to the whole ML1601c protein, the
synthetic peptides induced lower IFN-γ responses especially
in NEC and TB, as none of the peptides were recognized
by NEC and only p17 induced signiﬁcant responses in three
TB patients. Importantly, for the Brazilian EC only some
peptides (p15, p17, p20, and to a lesser extent p18) induced
signiﬁcant responses in multiple donors. Thus, these data
clearly indicate that peptide-induced IFN-γ production in
response to ML1601c are more speciﬁc for and correspond
with M. leprae exposure and/or infection.
3.2. Identiﬁcation of ML1601c Peptides with Discriminatory
Capacity. Since peptide responses are HLA restricted, a
combination of multiple M. leprae peptides will be required
to render a diagnostic test for leprosy broadly applicable.
Thus, for the selection of peptides with the best perfor-
mance in discriminating individuals with M. leprae infection
and/or exposure based on their capacity to induce IFN-
γ production in PBMC, a factor analysis was performedJournal of Tropical Medicine 5
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Figure 1: IFN-γ production by PBMC induced by SEB (a), PPD (b), M. leprae (c), and ML1601c recombinant protein (d) in MB (n = 11),
PB (n = 11), HHC (n = 19), TB (n = 8), and EC (n = 17) from Brazil as well as in Dutch NEC (n = 21). For NEC, PHA was used instead
of SEB. Values were corrected for background values. All background values were typically <20pg/mL. Horizontal bars indicate median
responses.
using the IFN-γ data (Figure 2) induced by all ML1601c
peptides and the ML1601c protein (Table 2).
This type of analysis has the potential to group together
peptides inducing comparable patterns of IFN-γ responses
and as a consequence presenting high correlations (factor
loadings) with the same factor. The 3 factors obtained
from the IFN-γ responses to the ML1601c protein and the
ML1601cpeptidescaninfactbelinkedtofeaturesrelevantin
the selection of peptides for use in diagnostic tests. Peptides
presenting high correlations with factor 1 (factor loading >
0.8; p3, p11, p12, p13, and p16) induce high-level responses
only in a subset of the exposed and/or infected individuals
(MB, PB, HHC) but not on those for which exposure is less
likely (EC), absent (NEC), or TB patients. Therefore, IFN-γ
production induced by these peptides was depicted for each
peptide separately as well as for the sum of the IFN-γ values
for all ﬁve of these ML1601c peptides combined (Figure 3).
This ﬁgure shows that IFN-γ levels in response to p13 were
most frequent but were also observed in three EC and in
one NEC, whereas p3, p11, and p16 showed very speciﬁc
responses only in leprosy patients and in M. leprae-exposed
HHC.ThisanalysisclearlyshowsthatM.leprae-speciﬁcIFN-
γ responsescanbeinducedselectivelyinPBMCderivedfrom
M. leprae exposed and/or infected individuals by peptides
derived from a protein that is not uniquely present in the M.
leprae genome. The ML1601c protein and p17 were highly
correlated with factor 2. Responsiveness to these two stimuli
was present in the exposed and/or infected groups, in the
EC and in TB patients. So, the ML1601c protein and p17
(correlated to factor 2) are not useful antigens in terms
of potentially discriminating M. leprae infection or disease.
ML1601c p15 and p20 (correlated to factor 3) share with the
factor 1 subset speciﬁcity for exposed and/or infected indi-
viduals. However, p15 and p20 also stimulate EC rendering
these peptides not useful for leprosy diagnostics either.
3.3. Whole Blood Assays Using ML1601c Peptides in Ethiopian
Healthy Controls. ML1601c p11 and p16 induced signiﬁcant
IFN-γ responses (>200pg/mL; Figure 3)i n1 0a n d1 1 M.
leprae-exposed or infected Brazilians, respectively, indicating
recognition of these peptides in the context of various
HLA alleles. Since one of the aims of this study was to
developﬁeld-friendlytestthatisworld-wideapplicable,IFN-
γ production in response to a mix of these peptides was
analyzed in a 24-hour WBA [20] using 34 healthy controls
from areas in Ethiopia with diﬀerent leprosy prevalence (Fig-
ure 4;E C low: n=16; EChigh: n=18). Although both groups
responded equally well to the positive control stimulus PHA
(Figure 4(a)), there was a signiﬁcant diﬀerence (P =0.0067)
between IFN-γ responses induced by the ML1601c peptide6 Journal of Tropical Medicine
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Figure 2: IFN-γ production by PBMC induced by ML1601c peptides (see Table 1)i nB r a z i l i a nM B( n = 11), PB (n = 11), HHC (n = 19),
TB (n = 8), and EC (n = 17) as well as Dutch NEC (n = 21). Values were corrected for background values. All background values were
typically <20pg/mL. Horizontal bars indicate median responses.
mix in individuals from an area with low endemicity (EClow)
compared to those from an area with high endemicity
(EChigh). Thus, WBA shows that IFN-γ levels, induced by
ML1601c peptides selected on the basis of IFN-γ responses
induced in M. leprae-exposed or infected individuals in
Brazil, can be detected as well in Ethiopian individuals ex-
posed to M. leprae.I F N - γ responses to these peptides in a
ﬁeld-friendly 24-hour WBA can therefore be used as indi-
cation of the magnitude of the M. leprae transmission level
in a given population.
3.4. Sequence Homology of ML1601c Peptides. Since M.
avium paratuberculosis contains a homologue of ML1601c
(MAP3249), the sequence of ML1601c was aligned with that
ofMAP3249,andtheaminoacididentitywasdeterminedfor
ML1601 peptides (Table 1). This alignment showed that the
percentage identity in general was not very high, with 42%
and 35% identical to MAP3249 for p11 and p16, respectively.
Immunogenicity of the peptides did not correlate with
the percentage identity, as p17 and p12 both had high
percentageidenticalsequence(52%and45%,resp.),butonly
p17 was recognized by many individuals. Thus, although
a homologue of ML1601c protein is present in M. avium
paratuberculosis, exact sequence identity is relatively low and
allows induction of speciﬁc T-cell responses in M. leprae-
exposed individuals by ML1601c peptides.
3.5. Multiplex Determination of Cytokines and Chemokines
in Response to ML1601c Peptides. Immunological correlates
of protection in leprosy are still lacking: although antigen-Journal of Tropical Medicine 7
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Figure 3: IFN-γ production by PBMC induced in all test groups by ML1601c peptides p3, p11, p12, p13, and p16 and the sum of the IFN-γ
values for p3, p11, p12, p13, and p16 combined. The proportions of responders in each test group are indicated below the x-axis.
speciﬁc IFN-γ production is often used as a biomarker
for M. leprae infection [9], it is possible that additional
cytokines might allow more speciﬁc or qualitatively diﬀerent
detection of immune responses against M. leprae peptides.
Inordertofurthercharacterizethecellularimmuneresponse
directed against ML1601c peptides, 15 additional cytokines
and chemokines were tested in multiplex assays on identical
supernatants as those used for IFN-γ (described above,
Figure 4) obtained from the 24-hour WBA stimulated with
a mix of ML1601c p11 and p16 using 34 healthy Ethiopian
individuals.
Although hardly any responses were detected for IL-
17, G-CSF, VEGF, IL-1α, IL-10, and GM-CSF nor any sig-
niﬁcant diﬀerences observed between EClow and EChigh for
the levels of IL-12, MIP-1β, MIG, and IL-8 (data not shown),
signiﬁcantly diﬀerent levels were observed between these
two groups when IL-1β (P = 0.0042), IL-6 (P = 0.0006),
IP-10 (P = 0.0001), TNF-α (P<0.0001), or MCP-1
(P = 0.0347) was measured (Figure 5). Thus, in addition
to IFN-γ, detection of these cytokines can also be used
to indicate the magnitude of the M. leprae transmission
level in a given population. Whether or not such cytokine8 Journal of Tropical Medicine
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Figure 4: IFN-γ production in response to the positive control PHA (a) or a mix of ML1601c peptides no. 11 and no. 16 (b) measured after
24h culture of undiluted whole blood derived from 34 Ethiopian healthy controls (ECs) derived from areas with low endemicity for leprosy
(EClow: n = 16) or from areas highly endemic for leprosy (EChigh: n = 18).
responses also indicate disease development or, alternatively,
protection from disease will as yet have to be determined
in longitudinal follow-up studies in HHC. Such studies are
currently underway in highly leprosy endemic areas.
4. Discussion
It is quite clear that elimination of leprosy requires, in ad-
dition to multidrug therapy (MDT), novel diagnostic tools
that allow early detection of preclinical M. leprae infection,
likely the major source of unidentiﬁed transmission. Also,
the fact that children are still developing leprosy suggests
that MDT has not substantially reduced transmission [1, 2].
Therefore, identifying antigens that can be used as tools
in diagnostic tests has been an important topic in leprosy
research the last two decades.
In classical, PBMC-based IFN-γ release assays, M. leprae
peptides have been shown to discriminate in a more speciﬁc
fashion than proteins between M. leprae-exposed contacts
and patients as opposed to healthy controls from the same
e n d e m i ca r e a[ 10, 12]. Our previous studies identiﬁed M.
leprae peptides derived from proteins such as ML1989,
ML1990, and ML2567 that induced IFN-γ in a 6-day
proliferation assay using PBMC. The slight disadvantage of
peptides though is that they usually induce signiﬁcantly low-
er levels of IFN-γ than proteins, particularly when whole
blood is used [13, 20]. This could, however, be inherent to
the selected peptides as for TB diagnosis; the combination of
>20 peptides is used successfully in WBA-based IGRA such
as QuantiFERON-TB Gold assay. Therefore, more peptides,
s h a r e di nd i ﬀerent M. leprae strains that can be applied
in diagnostic tools for leprosy, should be identiﬁed and
tested in the context of various genetic backgrounds in
South America, Asia, and Africa to enable development of
a peptide-based WBA.
The Brazilian population can roughly be divided in
three ethnic groups, namely, from Caucasian, indigenous,
and African descent. Given this genetical diversity and the
extraordinarily high leprosy endemicity compounded by
poverty in several of its areas, Brazil is a suitable region
for developing globally applicable T-cell-based diagnostic
tools. Indeed, this study shows that even HLA-restricted, M.
leprae peptides can be identiﬁed in a Brazilian population
and applied to measure M. leprae exposure in an African
population in Ethiopia. Two ML1601c peptides, p11 and
p16, only induced IFN-γ production in PBMC from leprosy
patients and HHC in Brazil and not, unlike ML1601c pro-
tein, in TB patients, EC, or NEC. The combination of these
peptides could be applied in a ﬁeld-friendly, 24h WBA in
Ethiopia to estimate exposure to M. leprae. This is consistent
with the ﬁndings of other M. leprae peptides (Martins et al.,
submitted) thereby indicating that combinations of peptides
can be designed and used eﬃciently to indicate substantial
exposure to M. leprae.
The observation in this study that ML1601c protein in-
duced signiﬁcant IFN-γ responses, in EC, TB, as well as
some NEC is in agreement with the ﬁnding that the use
of recombinant proteins coincides with an increased risk of
detecting cross-reactive T-cell responses irrespective of over-
all sequence homology. In addition, puriﬁcation and qua-
lity control assays for recombinant proteins are more labor
intensive than is the case for synthetic peptides. There-
fore, despite the fact that T-cell responses to peptides are
HLA restricted, which may limit the applicability of single
peptides with respect to diagnostic T-cell-based assays in
genetically diverse populations [21], a cocktail of M. lepraeJournal of Tropical Medicine 9
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Figure 5: Production of IL-1β (a), IL-6 (b), IP-10 (c), TNF-α (d), and MCP-1 (e) in response to selected ML1601c peptides measured after
24h culture of undiluted whole blood derived from 34 Ethiopian healthy controls (ECs) derived from areas with low endemicity for leprosy
(EClow: n = 16) or from areas highly endemic for leprosy (EChigh: n = 18).
peptides can be used to identify M. leprae exposure in gen-
etically diﬀerent populations.
An alternative approach that we addressed here is that
alternate cytokines or chemokines may be able to provide a
distinction between progression to disease and containment
of M. leprae infection. Therefore, we also tested supernatants
of whole blood cultures stimulated with ML1601c p11
and p16 for 15 additional cytokines: signiﬁcantly diﬀerent
levels were observed between EClow and EChigh when
IL-1β (P =0.0042), IL-6 (P =0.0006), IP-10 (P =0.0001),10 Journal of Tropical Medicine
TNF-α (P<0.0001), or MCP-1 (P = 0.0347) was used as
read-outs. Thus, in addition to IFN-γ, detection of these
cytokines can also be used to estimate the magnitude of
the M. leprae transmission level in a given population.
The signiﬁcant diﬀerences observed for both IL-1β and IL-6
suggest diﬀerences in the innate responses between the test
groups [22]. For TB susceptibility it has been described
that the polymorphism at the IL-1 locus inﬂuences the
cytokine response and may be a determinant of delayed-
type hypersensitivity and disease expression in human
tuberculosis [23]. For leprosy, however, no association with
IL-1β polymorphism has been described [24].
In combination with classical detection of anti-PGL-I
IgM antibodies, M. leprae peptide-based WBA measuring
cytokines will not only allow detection of most forms of
leprosy (PB and MB) but may also identify those at risk of
developing disease by detecting preclinical forms of leprosy,
thereby enabling installment of MDT at an early stage.
Additional M. leprae peptides will presumably be identiﬁed
in the future, but, to ensure the success of developing
an aﬀordable, ﬁeld-friendly test for the early diagnosis of
leprosy, continued funding for these eﬀorts will be critical.
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